Vincent Medical Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Raymond Choi

İcra Kurulu Başkanı

HK$1.5m

Toplam tazminat

CEO maaş yüzdesi	80.8%
CEO görev süresi	2yrs
CEO sahipliği	1.5%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	8.6yrs

Son yönetim güncellemeleri

Recent updates

Vincent Medical Holdings Limited's (HKG:1612) Shares Lagging The Market But So Is The Business

Oct 04

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Aug 23

Investors Met With Slowing Returns on Capital At Vincent Medical Holdings (HKG:1612)

May 21

Returns On Capital Are Showing Encouraging Signs At Vincent Medical Holdings (HKG:1612)

Dec 21

Vincent Medical Holdings (HKG:1612) Is Experiencing Growth In Returns On Capital

Aug 29

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

May 30

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Dec 15

One Analyst Thinks Vincent Medical Holdings Limited's (HKG:1612) Revenues Are Under Threat

Aug 07

Downgrade: Here's How This Analyst Sees Vincent Medical Holdings Limited (HKG:1612) Performing In The Near Term

Jul 27

Is Vincent Medical Holdings (HKG:1612) A Risky Investment?

Jun 06

One Vincent Medical Holdings Limited (HKG:1612) Analyst Just Slashed Their Estimates By A Material 13%

Mar 28

Vincent Medical Holdings Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Mar 25

Vincent Medical Holdings (HKG:1612) Knows How To Allocate Capital

Mar 23

Have Insiders Been Buying Vincent Medical Holdings Limited (HKG:1612) Shares This Year?

Mar 04

I Ran A Stock Scan For Earnings Growth And Vincent Medical Holdings (HKG:1612) Passed With Ease

Feb 17

Is There An Opportunity With Vincent Medical Holdings Limited's (HKG:1612) 42% Undervaluation?

Feb 04

What You Need To Know About Vincent Medical Holdings Limited's (HKG:1612) Investor Composition

Jan 22

Investors Who Bought Vincent Medical Holdings (HKG:1612) Shares A Year Ago Are Now Up 267%

Jan 08

Has Vincent Medical Holdings Limited's (HKG:1612) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Dec 26

What We Learned About Vincent Medical Holdings' (HKG:1612) CEO Compensation

Dec 14

CEO Tazminat Analizi

Raymond Choi'un ücretlendirmesi Vincent Medical Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	HK$64m
Mar 31 2024	n/a	n/a	HK$61m
Dec 31 2023	HK$2m	HK$1m	HK$57m

Tazminat ve Piyasa: Raymond 'ın toplam tazminatı ($USD 194.50K ) Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 229.76K ).

Tazminat ve Kazançlar: Raymond şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Raymond Choi (41 yo)

2yrs

Görev süresi

HK$1,515,000

Tazminat

Mr. Cheung Tai Choi, also known as Raymond, served as Deputy Chief Executive Officer of Vincent Medical Holdings Limited since January 1, 2022 until January 1, 2023 and serves as its Chief Executive Office...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Man Shing Choi	Executive Chairman	9.2yrs	HK$1.49m	1.68% HK$ 4.3m
Cheung Tai Choi	CEO & Executive Director	2yrs	HK$1.52m	1.48% HK$ 3.8m
Ming Fai Koh	VP of OEM Business & Executive Director	no data	HK$1.47m	0.78% HK$ 2.0m
Kwok Fu Fu	Executive Director	no data	HK$1.42m	0.93% HK$ 2.4m
Hoi Ming Lai	Chief Financial Officer	no data	Veri yok	Veri yok
Kar Kaan Liang	Associate Director of Operations	no data	Veri yok	Veri yok
Yuk Ming Wong	Vice President of Sales & Marketing	no data	Veri yok	Veri yok
Wing Kwan Tsui	Head of Corporate Sustainability & Development	no data	Veri yok	Veri yok
Changqing Zhang	Head of Sales & Marketing of Greater China	2.8yrs	Veri yok	Veri yok
Lai Ki Tsui	Company Secretary	7.7yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: 1612 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Man Shing Choi	Executive Chairman	9.2yrs	HK$1.49m	1.68% HK$ 4.3m
Cheung Tai Choi	CEO & Executive Director	2yrs	HK$1.52m	1.48% HK$ 3.8m
Ming Fai Koh	VP of OEM Business & Executive Director	8.8yrs	HK$1.47m	0.78% HK$ 2.0m
Kwok Fu Fu	Executive Director	8.8yrs	HK$1.42m	0.93% HK$ 2.4m
Yu Chiu Au	Independent Non-Executive Director	8.6yrs	HK$240.00k	Veri yok
Kwok Cheung Mok	Independent Non-Executive Director	8.6yrs	HK$276.00k	Veri yok
Kai Leung Yung	Independent Non-Executive Director	7.9yrs	HK$264.00k	Veri yok
Ming Chu Leung	Non Executive Director	1.5yrs	HK$99.00k	Veri yok

8.6yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1612 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/22 13:49
Gün Sonu Hisse Fiyatı	2025/01/22 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Vincent Medical Holdings Limited 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
E Wuen Tan	Crosby Securities Limited

Vincent Medical Holdings Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Vincent Medical Holdings Limited, Annual General Meeting, May 22, 2024

Executive Chairman recently bought HK$239k worth of stock

CEO & Executive Director recently bought HK$120k worth of stock

Vincent Medical Holdings Limited Appoints Leung Ming Chu as Non-Executive Director

Executive Chairman recently bought HK$103k worth of stock

Vincent Medical Holdings Limited Announces Retirement of Guo Pengcheng as Non-Executive Director

Recent updates

New major risk - Revenue and earnings growth

Vincent Medical Holdings Limited's (HKG:1612) Shares Lagging The Market But So Is The Business

First half 2024 earnings released: EPS: HK$0.052 (vs HK$0.041 in 1H 2023)

First half dividend increased to HK$0.016

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Vincent Medical Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024

Vincent Medical Holdings Limited to Report First Half, 2024 Results on Aug 21, 2024

Upcoming dividend of HK$0.015 per share

Investors Met With Slowing Returns on Capital At Vincent Medical Holdings (HKG:1612)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vincent Medical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.089 (vs HK$0.027 loss in FY 2022)

Vincent Medical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 21 June 2024

Vincent Medical Holdings Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Vincent Medical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Executive Chairman recently bought HK$239k worth of stock

Returns On Capital Are Showing Encouraging Signs At Vincent Medical Holdings (HKG:1612)

CEO & Executive Director recently bought HK$120k worth of stock

Vincent Medical Holdings (HKG:1612) Is Experiencing Growth In Returns On Capital

Upcoming dividend of HK$0.013 per share at 6.0% yield

First half 2023 earnings released: EPS: HK$0.041 (vs HK$0.068 loss in 1H 2022)

New minor risk - Dividend sustainability

Vincent Medical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 29, 2023

New major risk - Revenue and earnings growth

Vincent Medical Holdings Limited to Report First Half, 2023 Results on Aug 23, 2023

Vincent Medical Holdings Limited Appoints Leung Ming Chu as Non-Executive Director

Executive Chairman recently bought HK$103k worth of stock

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Vincent Medical Holdings Limited Announces Retirement of Guo Pengcheng as Non-Executive Director

Full year 2022 earnings: EPS exceeds analyst expectations

Vincent Medical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Vincent Medical Holdings Limited Announces FDA 510(K) Clearance of the Inspired Vhb20 Heated Humidifier

Vincent Medical Holdings Limited Announces Board Changes

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Now 21% undervalued

Less than half of directors are independent

Executive Chairman recently bought HK$417k worth of stock

Upcoming dividend of HK$0.025 per share

Vincent Medical Holdings Limited Announces Special Dividend for the Six Months Ended June 30, 2022, Payable on September 30, 2022

First half 2022 earnings released: HK$0.068 loss per share (vs HK$0.064 profit in 1H 2021)

One Analyst Thinks Vincent Medical Holdings Limited's (HKG:1612) Revenues Are Under Threat

Consensus revenue estimates fall by 18%

Vincent Medical Holdings' (HKG:1612) Returns Have Hit A Wall

Vincent Medical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

VP of Engineering & Executive Director recently bought HK$58k worth of stock

Vincent Medical Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Vincent Medical Holdings' (HKG:1612) Dividend Will Be Reduced To HK$0.025

Vincent Medical Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.025 per share

Vincent Medical Holdings' (HKG:1612) Dividend Will Be Reduced To HK$0.025

Price target decreased to HK$1.30

Less than half of directors are independent

Vincent Medical Holdings (HKG:1612) Will Pay A Smaller Dividend Than Last Year

Executive Chairman recently bought HK$211k worth of stock

Consensus revenue estimates fall by 22%

Under The Bonnet, Vincent Medical Holdings' (HKG:1612) Returns Look Impressive

Vincent Medical Holdings Limited to Report Fiscal Year 2021 Results on Mar 23, 2022

Vincent Medical Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2021

Investor sentiment improved over the past week

VP of Engineering & Executive Director recently bought HK$53k worth of stock

Executive Chairman recently bought HK$70k worth of stock

Executive Chairman recently bought HK$240k worth of stock

Executive Chairman recently bought HK$237k worth of stock

Upcoming dividend of HK$0.02 per share

First half 2021 earnings released: EPS HK$0.064 (vs HK$0.14 in 1H 2020)

Investor sentiment deteriorated over the past week

Downgrade: Here's How This Analyst Sees Vincent Medical Holdings Limited (HKG:1612) Performing In The Near Term

Consensus revenue estimates fall to HK$795.0m

Investor sentiment deteriorated over the past week